Accenture boosts supply chain capability with acquisition
Accenture has announced its acquisition of Australian-based supply chain and logistics consulting firm, GRA. This latest investment is the latest in Accenture's long-term global strategy to help boost the consulting firm's capabilities.
This latest acquisition from the global consulting firm is designed to strenthen Accenture’s Supply Chain & Operations capabilities that help public and private sector clients address complex supply chain demands to deliver dynamic customer experiences in line with responsible practices.
Founded in 1997, GRA has offices in Melbourne, Canberra and Brisbane with a team of 50 professionals. The firm Specialising in end-to-end supply chain and logistics strategies and operations, and working with some of Australia’s leading organisations in areas such as government, aerospace & defence and consumer goods, GRA's successful track record of "delivering value across a range of industries is exceptional", says Louise May, who leads Strategy & Consulting for Accenture in Australia and New Zealand.
Supply chains at a pivotal junction
The pandemic has accelerated the need for businesses to transform their supply chains to become more customer-focused, agile, and socially responsible with the flexibility to withstand future disruptions and this addition of GRA to the Accenture portfolio "will expand our supply chain and operations capabilities to help clients with their transformation to intelligent, customer-centric supply chains supporting profitable growth", says Tara Brady, country managing director for Accenture in Australia & New Zealand.
With a team of 50 professionals and offices in Melbourne, Canberra and Brisbane, GRA will bring its deep knowledge and skills in supply chain strategy, planning and execution to Accenture's extensive network of clients and partners.
“With supply chains across sectors at a pivotal junction, we are confident that this combination will enable both our team and clients to continue to grow and innovate at an accelerated pace," says Carter McNabb, founding partner at GRA.
Accenture boosting capabilities with multiple acquisitons
Accenture’s acquisition of GRA follows other investments across Australia and New Zealand in the past 18 months. These include the acqusition of cloud-native solutions provider Olikka in November 2020; of SAP and cloud solutions technology firm Zag in October 2020; and of data analytics and supply chain management company Icon Integration in February 2020.
Further acqusitions include that of business strategy and econometrics firm AlphaBeta in February 2020; specialist government consultancy Apis Group in December 2019 and big data and analytics company Analytics8 in August 2019.
Seo JungJin: Who is EY’s World Entrepreneur of 2021?
Seo JungJin, founder of biopharma firm Celltrion, which most recently developed an antibody treatment for COVID-19, has been named the EY World Entrepreneur of the Year 2021, becoming the first South Korean in the award’s 21-year history.
Regarded as one of the world’s most prestigious business awards program for entrepreneurs, the EY Entrepreneur of the Year celebrates visionary and innovative leaders from across 60 countries who are transforming the world and fostering growth.
JungJin, who is now honoroary chairman of Celltrion Group, was up against a worthy cast of entrepreneurial competitors, taking the crown from among 45 award winners across 38 countries and territories.
Speaking during the virtual event, JungJin described his own interpretation of entrepreneurship as something that brings together “a group of people toward a common vision, embracing challenges as opportunities and committing oneself to contribute to the greater good”.
Why was JungJin crowned King Entrepreneur?
A South Korean native and now 63 years of age, JungJin founded biopharmaceutical firm Celltrion in 2003. In the nearly two decades since its founding, Celltrion has lived up to its goal of advancing health and welfare for all by developing ground-breaking drugs to treat autoimmune disease, various forms of cancer and, most recently, COVID-19.
The company, which JungJin started with just US$45,000 and five of his colleagues, has since growth to more than 2,1000 employees with sales permits in more than 90 countries and revenues exceeding US$1.69bn.
According to the panel, JungJin’s story is a shining example of the power of an unstoppable entrepreneur to change the world with the pandel moved by both his incredible story and his purpose-driven leadership, innovative mindset and entrepreneurial spirit.
Described by the chair of the EY judging panel Rosaleen Blair as “representing everything an unstoppable should be” from taking on the world’s biggest health care challenges to consistently creating long-term value for his company, JungJin’s story is one of incredible tenacity and perseverance that the judging panel felt most represented the entrepreneurial spirit.
“He’s taken breathtaking risks, both personal and professional, to found Celltrion and grow it into one of the world’s leading biopharmaceutical companies,” says Stasia Mitchell, EY Global Entrepreneurship Leader. “His passion for creating affordable, life-saving health care and flair for tackling global problems has led to many treatments that have helped millions of people worldwide and was especially evident this past year through the creation of a COVID-19 antibody treatment.”
How did JungJin get there?
JungJin's entrepreneurial journey started at an early age when he worked as a taxi driver to get himself through Konkuk University in Seoul, South Korea. After studying industrial engineering, he rose through the ranks of Daewoo Motor Co. before losing his job amid the carmaker’s financial troubles following the 1997 Asian economic crisis.
Following this, JungJin started collaborating with colleagues to explore business opportunities in different industries, though none delivered lasting success. The turning point came after he attended a talk hosted by renowned scholars, which inspired him to focus on the biopharmaceutical sector.
And so he founded Celltrion with just US$45,000 of his savings. The launch of Remsima, credited with being the world's first antibody biosimilar, quickly moved Celltrion up the ranks of the country's fairly underdeveloped pharmaceutical sector. Celltrion followed this success with the launch of drugs for breast cancer and lymphoma that today are being used worldwide.
With ambitions to be the world’s first in different areas, Celltrion has pioneered numerous uncharted areas to great success over the past two decades, most recently responding to the global pandemic by successfully developing an antibody treatment for COVID-19 and working to ensure a timely supply of the safe and effective treatment.
“When I first started, my vision was to help patients gain access to safe, effective and affordable medicines and thereby enhance the quality of people’s lives,” explains JungJin. “The success of Celltrion has enabled me to expand on this while finding new ways to fuel my entrepreneurial drive.”